Affimed NV News

Company Name Stock Ticker Symbol Market Type
Affimed NV AFMD NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 3.28 20:00:00
Open Price Low Price High Price Close Price Prev Close
more quote information »

Recent News

Date Time Source Heading
8/04/202206:30GLOBEAffimed to Report Second Quarter 2022 Financial Results &..
6/30/202216:00GLOBEAffimed Establishes Scientific Advisory Board
6/23/202216:30TRMNSVB Securities Thinks Affimed’s Stock is Going to Recover
6/23/202207:29EDGARReport of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16..
6/10/202210:31GLOBEAffimed Presents Preclinical Data of Novel Innate Cell..
6/01/202206:54EDGARReport of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16..
6/01/202206:30GLOBEAffimed Reports First Quarter 2022 Financial Results and..
5/26/202217:05GLOBEAffimed Highlights Trial Designs of Three AFM24 Ongoing..
5/26/202206:30GLOBEAffimed to Present at the 2022 Jefferies Healthcare..
5/24/202206:30GLOBEAffimed Announces Annual General Meeting of Shareholders
5/16/202208:00GLOBEAffimed Presents Data on Innate Cell Engagers AFM24 and..
5/12/202210:31GLOBEAffimed to Present Preclinical Data Demonstrating Cytotoxic..
5/09/202215:25EDGARStatement of Ownership (sc 13g)
5/06/202216:02GLOBEAffimed Provides Update on ASCO AFM13-104 Oral Presentation
5/01/202212:42TRMNLeerink Partners Thinks Affimed’s Stock is Going to Recover
4/27/202217:20GLOBECORRECTING and REPLACING -- Affimed N.V.
4/27/202216:05GLOBEAffimed Announces Clinical Update and Trial in Progress..
4/21/202206:10EDGARStatement of Ownership (sc 13g)
4/18/202216:07EDGARReport of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16..
4/18/202211:28GLOBEAffimed Announces Closing of Public Offering of Common..
4/14/202216:18EDGARProspectus Filed Pursuant to Rule 424(b)(5) (424b5)
4/12/202222:02GLOBEAffimed Announces Pricing of Upsized $90 Million Public..
4/12/202216:02GLOBEAffimed Announces Proposed Public Offering of Common Shares
4/11/202222:08TRMNAffimed (AFMD) Initiated with a Buy at Leerink Partners
4/11/202207:25SEEKAffimed rises after data on blood cancer therapy from phase..
4/10/202212:05GLOBEAffimed Presents Updated Clinical Data from Phase 1/2 Study..
4/08/202213:23GLOBEAffimed Presents Findings from the Dose-escalation Phase of..
4/07/202206:06EDGARNotice of Effectiveness (effect)
4/01/202222:06TRMNLeerink Partners Thinks Affimed’s Stock is Going to Recover
4/01/202208:18TRMNAffimed (AFMD) Receives a Buy from Berenberg Bank
3/31/202216:44EDGARPost-effective Amendment to Registration Statement (pos Am)
3/31/202207:17EDGARReport of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16..
3/31/202207:11EDGARPost-effective Amendment to an Automatic Shelf Registration..
3/31/202206:34SEEKAffimed GAAP EPS of -€0.48, revenue of €40.37M
3/31/202206:30GLOBEAffimed Reports 2021 Financial Results and Highlights Recent..
3/30/202213:17SEEKAffimed FY 2021 Earnings Preview
3/24/202206:30GLOBEAffimed to Report Full Year 2021 Financial Results..
3/08/202216:35GLOBEAffimed Announces Clinical Updates at the Annual Meeting of..
2/14/202216:53EDGARAmended Statement of Ownership (sc 13g/a)
2/14/202216:46EDGARAmended Statement of Ownership (sc 13g/a)
2/09/202216:05GLOBEAffimed Announces Publication of Preclinical Data..
2/08/202206:30GLOBEAffimed to Present at Upcoming Investor Events
2/07/202216:42EDGARAmended Statement of Ownership (sc 13g/a)
2/07/202216:26EDGARStatement of Ownership (sc 13g)
1/06/202207:26EDGARReport of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16..
1/06/202206:30GLOBEAffimed Announces Completion of Enrollment in REDIRECT, the..
1/05/202206:30GLOBEAffimed to Present at the 40th Annual J.P. Morgan Healthcare..
12/13/202109:05GLOBEAffimed Shares Preclinical Data on Innate Cell Engagers..
12/09/202117:05TRMNBerenberg Bank Remains a Buy on Affimed (AFMD)
12/09/202106:30GLOBEAffimed to Host Virtual Investor Call Today to Discuss..

Your Recent History
Affimed NV
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now